This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-3933v1 69/5/1722    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, X. Articles by Spelsberg, T. C. Search for Related Content PubMed PubMed Citation Articles by Wu, X. Articles by Spelsberg, T. C.

The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor for Degradation in Breast Cancer Cells

Departments of ¹ Biochemistry and Molecular Biology, and ² Oncology, Mayo Clinic, Rochester, Minnesota

Requests for reprints: Thomas C. Spelsberg, Department of Biochemistry and Molecular Biology, Mayo Clinic, 16-01A Guggenheim Building, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-2480; Fax: 507-284-2053; E-mail: spelsberg.thomas{at}mayo.edu.

Key Words: breast cancer • endoxifen • tamoxifen • estrogen receptor • estrogen

Tamoxifen has been the most important therapeutic agent for the treatment of estrogen receptor (ER)-positive breast cancer for the past three decades. Tamoxifen is extensively metabolized by cytochrome P450 enzymes, and recent in vivo studies have shown that women with genetically impaired cytochrome P450 2D6 have reduced production of endoxifen and a higher risk of breast cancer recurrence. Despite these observations, the contribution of endoxifen to the overall drug effectiveness of tamoxifen remains uncertain. Here, we provide novel evidence that endoxifen is a potent antiestrogen that functions in part by targeting ER for degradation by the proteasome in breast cancer cells. Additionally, we show that endoxifen blocks ER transcriptional activity and inhibits estrogen-induced breast cancer cell proliferation even in the presence of tamoxifen, N-desmethyl-tamoxifen, and 4-hydroxytamoxifen. All of the effects of endoxifen are concentration dependent and do not occur at concentrations observed in human CYP2D6 poor metabolizers. These results support the theory that endoxifen is the primary metabolite responsible for the overall effectiveness of tamoxifen in the treatment of ER-positive breast cancer. [Cancer Res 2009;69(5):1722–7]

This article has been cited by other articles:

				W. Schroth, M. P. Goetz, U. Hamann, P. A. Fasching, M. Schmidt, S. Winter, P. Fritz, W. Simon, V. J. Suman, M. M. Ames, et al. Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen JAMA, October 7, 2009; 302(13): 1429 - 1436. [Abstract] [Full Text] [PDF]